SRR12696800
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- PROTEIN_SECRETION+0.500
- FATTY_ACID_METABOLISM+0.400
- ANDROGEN_RESPONSE+0.300
- CHOLESTEROL_HOMEOSTASIS+0.300
- DNA_REPAIR+0.300
- MTORC1_SIGNALING+0.300
- MYC_TARGETS_V2+0.300
- PEROXISOME+0.300
Top 10 suppressed
- KRAS_SIGNALING_DN-0.400
- IL6_JAK_STAT3_SIGNALING-0.300
- MYOGENESIS-0.300
- APICAL_JUNCTION-0.200
- INFLAMMATORY_RESPONSE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
- ALLOGRAFT_REJECTION-0.100
- ANGIOGENESIS-0.100
- COAGULATION-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 56D3154E-E779-4C27-8305-FEE7310B6762 | — | — | 0.820 |
| 2 | 92A04345-2DCA-49F5-801F-926B59255925 | — | — | 0.800 |
| 3 | 3A2D0D6F-66C3-48EE-9EA4-68668FF9B043 | — | — | 0.796 |
| 4 | 09E07A63-5FD2-4E4F-9FD5-2BB204302232 | — | — | 0.787 |
| 5 | 9B1A0E7C-F8DB-4FA0-9259-42A988D4E040 | — | — | 0.783 |
| 6 | SJEPD030784_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.783 |
| 7 | MNG570 | — | — | 0.778 |
| 8 | 3C612089-3AF3-4999-9F46-3EF083AFF90D | — | — | 0.775 |
| 9 | SRR23303753 | — | — | 0.772 |
| 10 | F2FCC449-3487-474C-82A6-8F2ED71E41BC | — | — | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.500 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |